Literature DB >> 18019627

Cancer of unknown primary.

L S Freudenberg1, S J Rosenbaum-Krumme, A Bockisch, W Eberhardt, A Frilling.   

Abstract

FDG-PET has been proven to be very sensitive in detecting a large variety of carcinomas. The FDG accumulation in malignant tumors is quite stereotyped and often reflects the aggressiveness of the tumor. Therefore, FDG appears to be suitable to detect unknown primaries independent of the type of disease. Being unaware of the site of the primary and also being unaware of the intensity of glucose metabolism, the interpretation of FDG-PET images needs rules accepting a reduced specificity for the definition of malignancy. However, due to physiological FDG-uptake in the head and neck area, especially in lymphatic tissue and vocal cords, one has to accept a high rate of equivocal findings interpreting FDG-PET alone. In this situation, the use of dual-modality PET/CT is of particular value. It allows for correlating the suspicious or unclear PET finding directly with morphology and by that the rate of false-equivocal or false-positive findings is reduced. In addition, PET/CT can precisely define the site of the PET finding in terms of anatomy, helping to direct the surgeon. This characteristic is of different value depending on the location of the primary and tends to be of utmost importance in the head and neck area. Finally, CT by itself may contribute with the detection of PET-negative findings. Thus in conclusion, PET and PET/CT can help localize the primary in CUP in approximately 40% of all cases, even after a thorough work-up with a variety of other investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18019627     DOI: 10.1007/978-3-540-31203-1_15

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  5 in total

1.  MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

Authors:  Manuela Ferracin; Massimo Pedriali; Angelo Veronese; Barbara Zagatti; Roberta Gafà; Eros Magri; Maria Lunardi; Gardenia Munerato; Giulia Querzoli; Iva Maestri; Linda Ulazzi; Italo Nenci; Carlo M Croce; Giovanni Lanza; Patrizia Querzoli; Massimo Negrini
Journal:  J Pathol       Date:  2011-06-01       Impact factor: 7.996

2.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

3.  Comparison of histopathological and gene expression-based typing of cancer of unknown primary.

Authors:  Lars Morawietz; Arno Floore; Lisette Stork-Sloots; Gunnar Folprecht; Reinhard Buettner; Anja Rieger; Manfred Dietel; Gerdt Huebner
Journal:  Virchows Arch       Date:  2009-12-10       Impact factor: 4.064

4.  Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.

Authors:  Christopher N Hueser; Nghi C Nguyen; Medhat Osman; Necat Havlioglu; Anjali J Patel
Journal:  World J Surg Oncol       Date:  2008-09-25       Impact factor: 2.754

5.  [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].

Authors:  L Morawietz; A Floore; L Stork-Sloots; G Folprecht; R Buettner; A Rieger; M Dietel; G Huebner
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.